Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Mayo Clin Proc. 2018 Aug;93(8):991–1008. doi: 10.1016/j.mayocp.2018.05.019

Figure 2:

Figure 2:

C3G triggers/associated disorders.

The percentage of patients with a monoclonal gammopathy, infection or an autoimmune laboratory finding at the time of development of renal disease is given for the total group of C3G, as well as for the C3GN and DDD subgroups.